INTERVENTION 1:	Intervention	0
Allo GM-CSF-secreting Vaccine, Trastuzumab, Cyclophosphamide	Intervention	1
vaccine	VO:0000001	22-29
cyclophosphamide	CHEBI:4026	44-60
Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.	Intervention	2
breast cancer	DOID:1612	28-41
breast cancer	DOID:1612	120-133
vaccine	VO:0000001	42-49
vaccine	VO:0000001	56-63
mixture	CHEBI:60004	77-84
mixed	BAO:0002107	186-191
x	LABO:0000148	79-80
x	LABO:0000148	188-189
x	LABO:0000148	199-200
x	LABO:0000148	213-214
patient	HADO:0000008,OAE:0001817	235-242
vaccination	VO:0000002	252-263
Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study	Intervention	3
cyclophosphamide	CHEBI:4026	0-16
Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously	Intervention	4
week	UO:0000034	134-138
Inclusion Criteria:	Eligibility	0
Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is defined as HER-2+ by immunohistochemistry (IHC) 3+ staining or Fluorescence In-Situ Hybridization (FISH). Prior adjuvant Trastuzumab therapy is permitted. Patients must not be eligible for therapy of known curative potential for metastatic breast cancer if it is identified during the course of the study.	Eligibility	1
adenocarcinoma	DOID:299	64-78
breast	UBERON:0000310	86-92
breast	UBERON:0000310	342-348
immunohistochemistry	BAO:0000415	123-143
adjuvant	CHEBI:60809	214-222
breast cancer	DOID:1612	342-355
Patients may have measurable or evaluable disease.	Eligibility	2
disease	DOID:4,OGMS:0000031	42-49
Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed.	Eligibility	3
stable	HP:0031915	0-6
central nervous system	UBERON:0001017	7-29
disease	DOID:4,OGMS:0000031	36-43
active	PATO:0002354	94-100
Age 18 years or older.	Eligibility	4
age	PATO:0000011	0-3
Able to give informed consent.	Eligibility	5
Patients with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.	Eligibility	6
group	CHEBI:24433	46-51
No systemic oral steroids administered within 28 days prior to initiating treatment on protocol. Topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes.	Eligibility	7
mucus	GO:0070701,UBERON:0000912	170-175
No prior or currently active autoimmune disease requiring management with systemic immunosuppression. This includes inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, sarcoidosis, or other rheumatologic disease. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.	Eligibility	8
active	PATO:0002354	22-28
autoimmune disease	DOID:417	29-47
inflammatory bowel disease	DOID:0050589	116-142
vasculitis	HP:0002633,DOID:865	153-163
scleroderma	HP:0100324,DOID:419,DOID:418	165-176
psoriasis	DOID:8893	178-187
multiple sclerosis	DOID:2377	189-207
hemolytic anemia	HP:0001878,DOID:583	209-225
thrombocytopenia	HP:0001873,DOID:1588	245-261
rheumatoid arthritis	HP:0001370,DOID:7148	263-283
systemic lupus erythematosus	HP:0002725,DOID:9074	285-313
syndrome	DOID:225	325-333
sarcoidosis	DOID:11335	335-346
disease	DOID:4,OGMS:0000031	40-47
disease	DOID:4,OGMS:0000031	135-142
disease	DOID:4,OGMS:0000031	371-378
disease	DOID:4,OGMS:0000031	420-427
asthma	HP:0002099,DOID:2841	380-386
chronic obstructive pulmonary disease	DOID:3083	390-427
Not pregnant, and on appropriate birth control if of child-bearing potential.	Eligibility	9
No history of other malignancies within the prior five years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, and superficial bladder cancer).	Eligibility	10
history	BFO:0000182	3-10
history	BFO:0000182	74-81
carcinoma	HP:0030731,DOID:305	85-94
skin cancer	DOID:4159	143-154
cancer	DOID:162	148-154
cancer	DOID:162	180-186
Adequate bone marrow reserve with absolute neutrophil count (ANC) > 1000 and platelets > 100,000.	Eligibility	11
bone marrow	UBERON:0002371	9-20
Adequate renal function with serum creatinine < 2.0.	Eligibility	12
function	BAO:0003117,BFO:0000034	15-23
creatinine	CHEBI:16737	35-45
Adequate hepatic reserve with serum bilirubin < 2.0, aspartate transaminase (AST) and alanine aminotransferase (ALT) < 2X the upper limit of normal, and alkaline phosphatase < 5X the upper limit of normal. Serum bilirubin > 2.0 is acceptable in the setting of known Gilbert's syndrome.	Eligibility	13
aspartate	CHEBI:29995	53-62
alanine	CHEBI:16449	86-93
phosphatase	GO:0016791,BAO:0000295	162-173
syndrome	DOID:225	276-284
Adequate cardiac reserve with a cardiac ejection fraction within the lower limit of facility normal by MUGA, or 45% by echocardiogram.	Eligibility	14
ejection fraction	CMO:0000180	40-57
No active major medical or psychosocial problems that could be complicated by study participation.	Eligibility	15
active	PATO:0002354	3-9
HIV negative.	Eligibility	16
Exclusion Criteria:	Eligibility	17
No histologic documentation of breast adenocarcinoma.	Eligibility	18
breast adenocarcinoma	DOID:3458	31-52
Breast adenocarcinoma that is not amplified for HER-2/neu gene expression by at least 2-fold by FISH analysis, or that is less than IHC 3+ when FISH negative.	Eligibility	19
breast adenocarcinoma	DOID:3458	0-21
gene expression	GO:0010467	58-73
Cardiac dysfunction documented by an ejection fraction less than the lower limit of the facility normal by multi-gated acquisition (MUGA) scan, or 45% by echocardiogram.	Eligibility	20
ejection fraction	CMO:0000180	37-54
Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest.	Eligibility	21
lung disease	DOID:850	22-34
dyspnea	HP:0002094	92-99
History of autoimmune disease as detailed above.	Eligibility	22
history	BFO:0000182	0-7
autoimmune disease	DOID:417	11-29
Systemic oral corticosteroid treatment within 28 days prior to initiating treatment on study.	Eligibility	23
corticosteroid	CHEBI:50858	14-28
Uncontrolled medical problems.	Eligibility	24
Evidence of active acute or chronic infection.	Eligibility	25
active	PATO:0002354	12-18
acute	HP:0011009,PATO:0000389	19-24
chronic infection	HP:0031035	28-45
Chemotherapy, radiation therapy, or biologic therapy (except Trastuzumab) within 28 days prior to initiating treatment on study. Hormonal therapy and supportive therapy with bisphosphonates will be allowed.	Eligibility	26
Participation in an investigational new drug trial within 28 days prior to initiating treatment on study.	Eligibility	27
drug	CHEBI:23888	40-44
Pregnant or breast feeding.	Eligibility	28
breast	UBERON:0000310	12-18
Hepatic, renal, or bone marrow dysfunction as detailed above.	Eligibility	29
bone marrow	UBERON:0002371	19-30
Concurrent malignancy or history of other malignancy within the last five years except as noted above.	Eligibility	30
history	BFO:0000182	25-32
Corn allergy.	Eligibility	31
allergy	HP:0012393	5-12
Known severe hypersensitivity to Trastuzumab (excluding mild to moderate infusion reactions that are easily managed and do not recur).	Eligibility	32
severe	HP:0012828	6-12
hypersensitivity	GO:0002524,DOID:1205	13-29
mild	HP:0012825	56-60
moderate	HP:0012826	64-72
Outcome Measurement:	Results	0
Number of Participants With Adverse Events	Results	1
Safety is measured as the number of patients that experienced adverse events related to study drug.	Results	2
drug	CHEBI:23888	94-98
Time frame: From first dose through 30 days after last dose of study drug, up to 9 months	Results	3
time	PATO:0000165	0-4
drug	CHEBI:23888	69-73
Results 1:	Results	4
Arm/Group Title: Allo GM-CSF-secreting Vaccine, Trastuzumab, Cyclophosphamide	Results	5
vaccine	VO:0000001	39-46
cyclophosphamide	CHEBI:4026	61-77
Arm/Group Description: Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.	Results	6
breast cancer	DOID:1612	51-64
breast cancer	DOID:1612	143-156
vaccine	VO:0000001	65-72
vaccine	VO:0000001	79-86
mixture	CHEBI:60004	100-107
mixed	BAO:0002107	209-214
x	LABO:0000148	102-103
x	LABO:0000148	211-212
x	LABO:0000148	222-223
x	LABO:0000148	236-237
patient	HADO:0000008,OAE:0001817	258-265
vaccination	VO:0000002	275-286
Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study	Results	7
cyclophosphamide	CHEBI:4026	0-16
Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously	Results	8
week	UO:0000034	134-138
Overall Number of Participants Analyzed: 20	Results	9
Measure Type: Count of Participants	Results	10
Unit of Measure: Participants  Fatigue: 8  40.0%	Results	11
fatigue	HP:0012378	31-38
Urticaria: 7  35.0%	Results	12
urticaria	HP:0001025,DOID:1555	0-9
Pruritus: 6  30.0%	Results	13
pruritus	HP:0000989,GO:0160025	0-8
Fever: 5  25.0%	Results	14
fever	HP:0001945	0-5
Flu-like symptoms: 4  20.0%	Results	15
Lymphadenopathy: 4  20.0%	Results	16
lymphadenopathy	HP:0002716	0-15
Abdominal pain: 3  15.0%	Results	17
abdominal pain	HP:0002027	0-14
Rash: 3  15.0%	Results	18
Malaise: 3  15.0%	Results	19
malaise	HP:0033834	0-7
Chills: 3  15.0%	Results	20
chills	HP:0025143	0-6
Dizziness: 2  10.0%	Results	21
Anorexia: 1   5.0%	Results	22
anorexia	HP:0002039	0-8
Erythema: 1   5.0%	Results	23
erythema	HP:0010783	0-8
Headache: 1   5.0%	Results	24
headache	HP:0002315	0-8
Nausea: 1   5.0%	Results	25
nausea	HP:0002018	0-6
Arm pain: 1   5.0%	Results	26
pain	HP:0012531	4-8
Cancer site pain: 1   5.0%	Results	27
cancer	DOID:162	0-6
site	BFO:0000029	7-11
pain	HP:0012531	12-16
Leg pain: 1   5.0%	Results	28
leg	UBERON:0000978	0-3
pain	HP:0012531	4-8
Groin tightness: 1   5.0%	Results	29
Erythema at vaccine sites: 20 100.0%	Results	30
erythema	HP:0010783	0-8
vaccine	VO:0000001	12-19
Pruritus at vaccine sites: 20 100.0%	Results	31
pruritus	HP:0000989,GO:0160025	0-8
vaccine	VO:0000001	12-19
Induration at vaccine sites: 20 100.0%	Results	32
vaccine	VO:0000001	14-21
Pain at vaccine sties: 17  85.0%	Results	33
pain	HP:0012531	0-4
vaccine	VO:0000001	8-15
Rash at vaccine sites: 7  35.0%	Results	34
vaccine	VO:0000001	8-15
Blister at vaccine sites: 5  25.0%	Results	35
vaccine	VO:0000001	11-18
Hyperpigmentation at vaccine sites: 4  20.0%	Results	36
vaccine	VO:0000001	21-28
Bruising at vaccine sites: 3  15.0%	Results	37
vaccine	VO:0000001	12-19
Edema at vaccine sites: 2  10.0%	Results	38
edema	HP:0000969	0-5
vaccine	VO:0000001	9-16
Vaccine site flare: 2  10.0%	Results	39
vaccine	VO:0000001	0-7
site	BFO:0000029	8-12
Adverse Events 1:	Adverse Events	0
Total: 1/20 (5.00%)	Adverse Events	1
Urticaria *1/20 (5.00%)	Adverse Events	2
urticaria	HP:0001025,DOID:1555	0-9
